Enphase Energy Inc vs uniQure N.V. Ordinary Shares — how do they compare? Enphase Energy Inc trades at $28.88 (market cap $4.23B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Enphase Energy Inc is far larger — about 2.9× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ENPH | QURE | |
|---|---|---|
Market Cap | $4.23B | $1.45B |
Volume | 4,755,897 | 3,323,243 |
Sector | Energy | Health |
52-Week High | $72.33 | $70.59 |
52-Week Low | $26.12 | $9.03 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $3.88B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.03, up 1.71% on the day, with a bearish technical signal but oversold RSI suggesting potential for a bounce. Revenue declined to $1.47B in 2025 from $2.3B in 2023, though net income margin improved to 11.68%. Recent news highlights product approvals and AI infrastructure developments, yet the stock faces pressure from high borrowing costs impacting the solar sector.
The outlook is mixed: analyst consensus targets $42.68 (33% upside) with 42% buy ratings, but earnings misses and solar industry headwinds pose risks. Investment opportunity hinges on execution amid competitive and macroeconomic challenges, with current valuation at a P/E of 31.71 reflecting growth expectations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →